J84.82
Adult pulmonary Langerhans cell histiocytosis
Clinical Classification Guidelines
Inclusion Terms
- Adult PLCH
Medical Intelligence & Overview
Adult Pulmonary Langerhans cell Histiocytosis (PLCH) is a rare lung disorder characterized by the abnormal growth of Langerhans cells, a type of immune cell, within the lung tissue. This condition primarily affects young to middle-aged adults and is strongly linked to cigarette smoking. Over time, the accumulation of these abnormal cells can lead to lung tissue damage, resulting in symptoms like cough and breathing difficulties. Recognizing and understanding PLCH is important for early diagnosis and management, although it remains a complex condition with no definitive cure.
Causes & Symptoms
Clinical Causes: Strong association with cigarette smoking, which is considered the primary risk factor Potential genetic predispositions, although these are not well understood Environmental exposures and inhaled toxins may contribute less significantly
Key Symptoms: Persistent cough Shortness of breath, especially during physical activity Chest discomfort or pain Fatigue and weakness Wheezing or abnormal lung sounds Unintentional weight loss in advanced cases
Diagnostic & Treatment
Diagnosis Path: Diagnosing adult pulmonary Langerhans cell histiocytosis involves a combination of clinical evaluation and specialized testing. Physicians may perform:
Treatment Protocols: While there is no universally approved cure for adult PLCH, treatment strategies focus on managing symptoms, halting disease progression, and improving quality of life. Approaches include:
Clinical Advice & FAQs
Billing Guidance
Is J84.82 a billable ICD-10 code?
Yes, J84.82 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report J84.82?
Clinical documentation must specify the nature of Adult pulmonary Langerhans cell histiocytosis and any associated comorbidities for accurate reporting.
Cite this Clinical Reference